Ricerca avanzata

Home > Riviste > Minerva Cardioangiologica > Fascicoli precedenti > Minerva Cardioangiologica 2015 Agosto;63(4) > Minerva Cardioangiologica 2015 Agosto;63(4):329-42

FASCICOLI E ARTICOLI   I PIÙ LETTI   eTOC

ULTIMO FASCICOLOMINERVA CARDIOANGIOLOGICA

Rivista sulle Malattie del Cuore e dei Vasi

Official Journal of the Italian Society of Angiology and Vascular Pathology
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,752

Periodicità: Bimestrale

ISSN 0026-4725

Online ISSN 1827-1618

 

Minerva Cardioangiologica 2015 Agosto;63(4):329-42

 REVIEW

Management of cardiogenic shock in the setting of ST-elevation myocardial infarction: controversies and future directions

Kohl L. P. 1, Jones W. S. 1, 2

1 Division of Cardiology, Duke Heart Center, Duke University Medical Center, Durham, NC, USA;
2 Duke Clinical Research Institute, Durham, NC, USA

The treatment of patients with ST-segment elevation myocardial infarction (STEMI) has changed dramatically since reperfusion therapy has been adopted more commonly, yet 5-10% of patients still develop cardiogenic shock and remain a therapeutic challenge in the setting of STEMI. In this review, we outline the available evidence from randomized controlled trials and registries, including risk factors, diagnostic tools, and various treatments. The main focus of this report is on the currently available treatment options (revascularization, intra-aortic balloon counterpulsation), emerging treatment options (percutaneous hemodynamic support, extracorporeal membrane oxygenation), and ongoing efforts to design systems of care to more efficiently care for these patients.

lingua: Inglese


FULL TEXT  ESTRATTI

inizio pagina